Advanced Solid Tumors ARTISTRY-3
Phase 1

By Mural Oncology | July 29, 2024

Dosing: Nemvaleukin (IV) Monotherapy and Combination with Pembrolizumab (Potentially
Registrational)

Anticipated Program Milestone:
Interim readout expected in Q1 2025 (subject to patient enrollment)